|
Video: What is a Stock Split?
|
|
Xeris Biopharma Holdings is a pharmaceutical company. Co.'s primary focus is on therapies for patient populations in endocrinology, neurology, and gastroenterology. Co.'s products include: Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes ages two years and older; Keveyis, the U.S. Food and Drug Administration approved therapy for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev (levoketoconazole), a cortisol synthesis inhibitor used for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. According to our Xeris Biopharma Holdings stock split history records, Xeris Biopharma Holdings has had 0 splits. | |
|
Xeris Biopharma Holdings (XERS) has 0 splits in our Xeris Biopharma Holdings stock split history database.
Looking at the Xeris Biopharma Holdings stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Xeris Biopharma Holdings shares, starting with a $10,000 purchase of XERS, presented on a split-history-adjusted basis factoring in the complete Xeris Biopharma Holdings stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
06/22/2018 |
|
End date: |
05/01/2024 |
|
Start price/share: |
$18.80 |
|
End price/share: |
$1.75 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-90.69% |
|
Average Annual Total Return: |
-33.30% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$930.78 |
|
Years: |
5.86 |
|
|
|
|
|